Synonym
CT-2584 mesylate; CT-2584 MESYLATE; CT-2584HMS; CT-2584 HMS
IUPAC/Chemical Name
1-(11-(dodecylamino)-10-hydroxyundecyl)-3,7-dimethyl-3,7-dihydro-1H-purine-2,6-dione methanesulfonate
InChi Key
RCBJUJRVBGYTEO-UHFFFAOYSA-N
InChi Code
InChI=1S/C30H55N5O3.CH4O3S/c1-4-5-6-7-8-9-10-13-16-19-22-31-24-26(36)21-18-15-12-11-14-17-20-23-35-29(37)27-28(32-25-33(27)2)34(3)30(35)38;1-5(2,3)4/h25-26,31,36H,4-24H2,1-3H3;1H3,(H,2,3,4)
SMILES Code
CS(O)(=O)=O.CCCCCCCCCCCCNCC(O)CCCCCCCCCN1C(=O)N(C)C2=C(N(C)C=N2)C1=O
Appearance
To be determined
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 -4 C for short term (days to weeks) or -20 C for long term(months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
629.90
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Bonfil RD. CT-2584 (Cell Therapeutics). Curr Opin Investig Drugs. 2001 Mar;2(3):424-7. PubMed PMID: 11575717.
2: Cheeseman SL, Brannan M, McGown A, Khan P, Gardner C, Gumbrell L, Dickens D, Ranson M. Phase I and pharmacologic study of CT-2584 HMS, a modulator of phosphatidic acid, in adult patients with solid tumours. Br J Cancer. 2000 Dec;83(12):1599-606. PubMed PMID: 11104552; PubMed Central PMCID: PMC2363467.
3: Finney RE, Nudelman E, White T, Bursten S, Klein P, Leer LL, Wang N, Waggoner D, Singer JW, Lewis RA. Pharmacological inhibition of phosphatidylcholine biosynthesis is associated with induction of phosphatidylinositol accumulation and cytolysis of neoplastic cell lines. Cancer Res. 2000 Sep 15;60(18):5204-13. PubMed PMID: 11016649.
4: Khan P, Abbas S, Cheeseman S, Ranson M, McGown AT. Development and validation of a sensitive solid-phase extraction and high-performance liquid chromatography assay for the novel antitumour agent CT2584 in human plasma. J Chromatogr B Biomed Sci Appl. 1999 Jan 22;721(2):279-84. PubMed PMID: 10052700.
5: Phase I clinical data on novel anticancer, antiangiogenesis drug. Oncology (Williston Park). 1998 Sep;12(9):1395. PubMed PMID: 9778687.
6: Marucci L, Varticovski L, Arias IM. Effect of a xanthine analog on human hepatocellular carcinoma cells (Alexander) in culture and in xenografts in SCID mice. Hepatology. 1997 Nov;26(5):1195-202. PubMed PMID: 9362362.
7: Shau H, Kim AT, Hedrick CC, Lusis AJ, Tompkins C, Finney R, Leung DW, Paglia DE. Endogenous natural killer enhancing factor-B increases cellular resistance to oxidative stresses. Free Radic Biol Med. 1997;22(3):497-507. PubMed PMID: 8981042.
8: MOUNT RA, FLOYD TM. A dysentery outbreak aboard a cruiser in Apra Harbor, Guam, Marianas Islands. U S Nav Med Bull. 1948 Mar-Apr;48(2):240-9. PubMed PMID: 18906975.
